ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GANX Gain Therapeutics Inc

2.50
0.00 (0.00%)
Pre Market
Last Updated: 07:52:50
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 2.42
Ask Price 3.50
News -
Day High

Low
2.00

52 Week Range

High
5.33

Day Low
Company Name Stock Ticker Symbol Market Type
Gain Therapeutics Inc GANX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 2.50 07:52:50
Open Price Low Price High Price Close Price Prev Close
2.50
Trades Volume Avg Volume 52 Week Range
0 0 - 2.00 - 5.33
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.50 USD

Gain Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
31.76M 12.91M - 55k -22.11M -1.71 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Gain Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GANX Message Board. Create One! See More Posts on GANX Message Board See More Message Board Posts

Historical GANX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.452.832.402.6191,4550.052.04%
1 Month3.543.652.342.75120,681-1.04-29.38%
3 Months4.645.192.343.62120,870-2.14-46.12%
6 Months2.215.332.003.75138,3330.2913.12%
1 Year4.975.332.003.7389,646-2.47-49.70%
3 Years10.6910.9992.004.9582,309-8.19-76.61%
5 Years11.2217.932.005.5484,090-8.72-77.72%

Gain Therapeutics Description

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements.

Your Recent History

Delayed Upgrade Clock